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Abstract. This paper summarizes our current understanding of the biology of Plasmodium vivax, how it differs from
Plasmodium falciparum, and how these differences explain the need for P. vivax-tailored interventions. The article fur-
ther pinpoints knowledge gaps where investments in research are needed to help identify and develop such specific
interventions. The principal obstacles to reduce and eventually eliminate P. vivax reside in 1) its higher vectorial capac-
ity compared with P. falciparum due to its ability to develop at lower temperature and over a shorter sporogonic cycle
in the vector, allowing transmission in temperate zones and making it less sensitive to vector control measures that
are otherwise effective on P. falciparum; 2) the presence of dormant liver forms (hypnozoites), sustaining multiple
relapsing episodes from a single infectious bite that cannot be diagnosed and are not susceptible to any available
antimalarial except primaquine, with routine deployment restricted by toxicity; 3) low parasite densities, which are
difficult to detect with current diagnostics leading to missed diagnoses and delayed treatments (and protracted
transmission), coupled with 4) transmission stages (gametocytes) occurring early in acute infections, before infection
is diagnosed.
INTRODUCTION
A better understanding of Plasmodium vivax biology and
how it differs from Plasmodium falciparum could help to
better target research and interventions that would allow us
to intensify control and possibly eliminate vivax malaria.
The knowledge and knowledge gaps in P. vivax biology are
grouped into several intertwined topics: 1) liver stages:
hypnozoites and relapses, 2) asexual blood stages and mero-
zoite invasion, 3) asexual blood stages and diagnosis, 4) sex-
ual blood stages and transmission, 5) mosquito stages and
vectorial capacity, 6) immunity, 7) pathogenesis, and 8) genetic
diversity. Herein, we discuss in turn each of these topics and
their implications for the control of P. vivax malaria (summa-
rized in Table 1 and Figure 1).
LIVER STAGES: HYPNOZOITES AND RELAPSES
Persistent quiescent liver forms (hypnozoites) cause relapse
infections, generating cases without further sporozoite inocula-
tions by mosquitoes. The latency periods between relapse epi-
sodes are strain specific and influenced by the inoculum size,
though relapses could also be triggered by external mecha-
nisms, inflammation possibly being one. Radical cure requires
the elimination of the hypnozoites. Relapses help maintain
the parasite’s genetic diversity and reduce its reliance on mos-
quito transmission for sustenance, hence diminishing the effec-
tiveness of vector control measures.
There are no current diagnostics to detect hypnozoites.
Understanding the mechanisms of hypnozoite quiescence and
reactivation and developing a safe radical cure are the two
most urgent research priorities, but in vitro and in vivo models
suitable for biological investigations and drug screening are
required to achieve these objectives.1
Hypnozoites are evolutionary adaptations present only
in the human malaria parasites P. vivax and Plasmodium
ovale, and a few nonhuman primate species, notably Plas-
modium cynomolgi of macaques, which has long been
used as an in vivo model. Histologically, hypnozoites are
small, uninucleated parasites that can be visualized by
staining with specific antibodies but remain difficult to
detect because they are present in low numbers even
in hosts given massive inocula.2 The biology of these
nongrowing, nondividing parasites is largely unknown.
Hypnozoites can persist for more than a year in their host
cell, the hepatocyte, in a state of reduced metabolic activ-
ity, which protects them from all antimalarials except for
some 8-aminoquinolines, which presumably act through
oxidative stress.
The mechanisms regulating hypnozoite dormancy and
reactivation remain obscure. Different parasite strains dis-
play distinct relapse patterns, ranging from one in which
the primary infection occurs several (9–12) months follow-
ing the infective bite, which is typical of strains from tem-
perate regions including Korean, some Chinese, and the old
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north European/Russian or “hibernans” strains, to the other
extreme where the primary episode occurs 14−21 days after
infection followed by a succession of relapses at roughly
monthly intervals typified by the tropical Chesson strain
from Papua New Guinea (PNG)3 (see Figure 2). Strains mid-
way between these examples with mixed relapse patterns are
known and probably frequent, but it is problematic to deter-
mine this pattern in endemic regions because distinguishing
new infections from relapses is difficult.4
It is not ordinarily possible to distinguish primary infec-
tions from subsequent relapses. Two subsequent, genetically
identical infections could either be from a failure to clear the
bloodstream completely of parasites (recrudescence) or acti-
vation of a hypnozoite in the liver (relapse). When study-
ing infants with no previous infections, relapses are usually
homologous to the initial strain. In most studies, including
studies in travelers with time-limited exposures in endemic
countries, relapses were found to be genetically distinct5,6
but related7 to either the initial infections or a previous
relapse. In drug efficacy studies, it is therefore often possible
to distinguish relapses from recrudescence (i.e., if the initial
and subsequent parasites are genetically distinct), but not
between a relapse and a new infection.
Factors in addition and external to genetic and epige-
netic control, such as inflammation, are also likely to trigger
hypnozoite activation. Historical and more recent observa-
tions suggest that febrile responses from some infections
(such as a P. falciparum, typhoid fever or relapsing fever)
but not others (influenza) could precipitate P. vivax relapse.8
Toll-like receptors, which activate innate immune responses,
could also play a role in hypnozoite activation.9 Much more
research is needed to decipher the underlying genetic mecha-
nisms and environmental factors that may influence relapse
patterns and hypnozoite activation.
Plasmodium vivax relapse poses a major challenge to
the control and elimination of this species because the mul-
tiple episodes can exacerbate the total morbidity resulting
from each infection and substantially prolong the duration
TABLE 1
Main characteristics of Plasmodium vivax biology and their implications
Characteristic Consequence Implications for control Implications for research
Hypnozoites: dormant
parasites in the liver
Relapses: (a) generate
parasitological and clinical
episodes without reinfection,
(b) help maintain genetic diversity
Radical cure requires
elimination of hypnozoites.
Only 8-aminoquinolines
available to date but use
limited by toxicity
Need to develop reproducible
in vitro and in vivo models
to understand mechanisms
of quiescence and activation
No diagnostic to identify
subjects with potential
for relapses
Need to discover and test new
medications for radical cure
Recurrent cases cannot be
prevented via vector control
Need to develop diagnostics
for liver-stage parasites
Asexual blood stages:
preference for reticulocytes
and low pyrogenic threshold
Morbidity with low parasite
densities, and parasitaemia
undetectable with
conventional methods
Difficult to diagnose with rapid
diagnostic tests or microscopy
Need to develop continuous
in vitro culture systems
Delayed diagnosis and treatment
(especially relapsing episodes)
Need to develop new,
more sensitive diagnostics
for blood-stage parasites
Anemia Protracted transmission
Prevalence underestimated
Mature gametocytes appear
almost simultaneously with
asexual forms
Transmission occurs before
diagnosis, and treatment
on occasion of primary
infection and relapses
Early treatment cannot prevent
transmission for current episode
Resistance is not spread
as efficiently as in
Plasmodium falciparum
Entomological surveys required
to tailor vector control measures
Vectorial capacity: can
complete its development
cycle in the mosquito at lower
temperature and more quickly
than P. falciparum
(a) Larger endemic geographic range
into temperate region
(a) Not confined to tropical climates
(b) Less susceptible to vector
control measures that reduce
mosquitos’ life span
(b) Vector control via indoor
residual spraying may be
not as effective as for
P. falciparum
Immunity Clinical immunity acquired
earlier in life
Burden of disease in young children
in high-transmission areas
More studies needed to
improve understanding
of immunity to P. vivax vs.
P. falciparum
Higher molecular force of infection
caused by relapses independent
of inoculation rate
Rate of infections increases with age
Pathogenesis High flexibility of reticulocytes
allows escaping splenic removal
without sequestration: relative
lack of severe manifestations
Burden of disease underestimated Develop better surveillance
tools to more accurately
map vivax burden of disease
However, significant morbidity
(debilitation, anemia) and
evidence of severity and fatality
Higher genetic diversity Association with epidemiology
not yet clear
More stable transmission More studies needed in a
range of transmission settings
Sustained at low transmission More difficult to control More complex vaccine target
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of the infection. Thus, the potential for transmission onto
new hosts, whether infections are symptomatic or asymp-
tomatic, is greatly increased. Understanding the mecha-
nisms of hypnozoite quiescence and reactivation, as well as
developing a safe radical cure are the two most urgent
research priorities.1 Currently, these and other aspects
of hypnozoite biology can be investigated experimentally
only in part using the traditional P. cynomolgi-infected
rhesus macaque model because of the inherent biological,
economical, and ethical limitations. These limitations also
restrict the number of molecules that can be tested for
activity against the hypnozoite. Recently, hypnozoites were
obtained in a long-term in vitro culture of P. cynomolgi-
infected primary simian hepatocytes, opening the way to
initiate investigations on the biological nature of the
hypnozoites and to conduct cost-effective low- to medium-
throughput screening of compounds to identify novel leads
for radical cure.10,11 Similar in vitro, as well as in vivo, systems
for drug screening and studying P. vivax hypnozoite biology
are being developed.12,13
ASEXUAL BLOOD STAGES AND MEROZOITE
INVASION
A distinct biological feature for P. vivax regarding its inva-
sion and growth in host erythrocytes is its dependence on
the Duffy blood group antigen expressed at the erythrocyte
surface, although apparently Duffy-negative individuals can
also become infected under some circumstances.
Until recently, it was commonly accepted that P. vivax
merozoites could invade only erythrocytes expressing the
Duffy blood group antigen (also known as Duffy antigen
chemokine receptor [DARC]). This dependence on DARC
explained why the geographic distribution of P. vivax coin-
cided predominantly with tropical and temperate areas where
the Duffy blood group is expressed on the surface of
FIGURE 2. Patterns of primary attack and relapse of the principal Plasmodium vivax strains.
FIGURE 1. Plasmodium vivax cycle and main biological characteristics.
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erythrocytes, which is the case for most human populations,
except for sub-Saharan Africa. However, some recent data
have challenged this belief. Evidence recently acquired in
Madagascar, Kenya, Brazil, and elsewhere indicates that
P. vivax can infect Duffy-negative individuals, albeit these
infections may not be nearly as robust as in Duffy-positive
individuals.14 Concern has been expressed that in areas
with large interspersed populations of both Duffy-negative
and Duffy-positive people, P. vivax might be evolving to
infect human populations lacking the erythrocytic expression
of DARC.15 Although this is presently only speculation, moni-
toring for P. vivax infections in Duffy-negative populations in
Africa should be considered.16
The parasite ligand for DARC, Duffy binding protein
(DBP), localized in the apical (invasive end) organelles of
the merozoite, is a member of an intra- and interspecies fam-
ily of invasion ligands known as Duffy binding protein–like
(DBL) or, alternatively, erythrocyte binding protein–like
(EBL) proteins. Most species of Plasmodium have multiple
DBL/EBL family members in their genomes that mediate
alternative pathways for invading red blood cells (RBCs).
Until recently, sequencing of the genome of the Salvador I
strain of P. vivax had indicated that DBP was the only DBL
and thus likely no alternative invasion pathways existed to
escape the lack of the DARC receptor. However, recent
sequencing of genomes from other strains of P. vivax indicate
there is a second duplicated DBP gene in the genomes of many
isolates of P. vivax, observed originally in Madagascar14,17 and
also throughout southeast Asia17 as well as a second DBL gene
present and expressed in most strains, P. vivax erythrocyte-
binding protein which, theoretically, might mediate invasion
in Duffy-negative erythrocytes.18,19
DBP may be an important vaccine target as a cysteine-rich
region mediates the specific binding of this invasion ligand
to DARC. This binding domain, while mostly conserved,
nevertheless exhibits considerable amino acid polymorphism
outside the binding pocket while retaining its binding speci-
ficity. As a consequence, most blocking antibodies against
the binding domain, while able to inhibit the interaction of
DBP with DARC with homologous parasites and molecules,
do not bind or show reduced binding to heterologous vari-
ants of DBP, although some immune individuals elicit anti-
bodies that are able to cross this immunological barrier and
inhibit DBP/DARC interactions for many different allelic
variants of P. vivax DBP. Similar to apical membrane antigen-
1-based vaccines for P. falciparum, vaccines based on DBP
may need to contain several different allelic forms of the
invasion ligand to be effective.20,21
The basis for preferentially invading reticulocytes is the
presence in P. vivax merozoites of two large high molecular
weight (> 300 kDa) proteins that bind specifically to reticu-
locytes, independently of DARC. These two invasion ligand
proteins were originally termed reticulocyte binding protein
1 and 2 (RBP-1 and RBP-2). As with DBP and the DBL
gene family, the RBPs are part of a large intra- and interspe-
cies family of invasion ligands termed the RBP-like (RBL)
proteins. Genome sequencing has revealed that there are
at least six other RBL genes in the genome of P. vivax in
addition to RBP-1 and RBP-2. However, most appear to
be pseudogenes and likely not expressed, although tran-
scripts might be detectable. RBP-1 is not very polymorphic
with only three of 3,000 potential sites of non-synonymous
changes noted. RBP-2c has a much greater number of non-
synonymous mutations that produce the greatest number
of amino acid substitutions, which could indicate that the
RBP-2c ligand is important for reticulocyte invasion. It could
also suggest allele-specific immune responses might be a
challenge facing the development of RBL-targeting vaccines
in the future. Recently, RBP-2a was shown to bind mature
RBCs, and its crystal structure indicated structural similarity
to the essential P. falciparum invasion ligand Rh5.22 Although
the function(s) of the P. vivax RBL ligands are not fully
understood, it is possible that these genes also serve as alter-
native pathways to invasion or for redundancy in the same
pathway for invasion of reticulocytes.21,23,24
ASEXUAL BLOOD STAGES AND DIAGNOSIS
Compared with P. falciparum, parasitaemia and pyrogenic
threshold (the number of parasites that trigger a symptom-
atic malaria attack) are lower in P. vivax infections. The
lower parasitaemia thus means that diagnosis and treatment
are often delayed or missed entirely. This scenario is even
more likely for relapse infections as parasite levels are lower
and often less symptomatic with each successive relapse as a
consequence of the gradual acquisition of anti-blood stage
immunity. Consequently, prevalence is underestimated while
transmission potential is enhanced, particularly as commit-
ment to gametocyte production occurs early in the infec-
tion. Developing more sensitive diagnostic tools is a public
health priority.
The strict preference for reticulocytes (generally around
0.5–1.5% of the total circulating erythrocytes) along with
the relatively rapid acquisition of immunity explain the lower
parasite levels observed during P. vivax infection, generally
restricting peak parasite levels below 20,000 parasites per
microliter of blood. This occurs even when reticulocyte levels
increase in response to the profound anemia caused by high
levels of destruction of mature uninfected erythrocytes dur-
ing P. vivax infections.25
Vivax malaria has a lower pyrogenic threshold than
P. falciparum infections in all groups of individuals such that
fever and symptoms can occur with parasitemias undetectable
by routine diagnostics: in a nonimmune host experiencing
a P. vivax infection, the first febrile symptoms often occur
2−3 days before the parasites can be reliably detected in the
peripheral blood by microscopy, though the parasites can be
detected by polymerase chain reaction (PCR)–based assays.
Data from Thailand indicate that the pyrogenic threshold for
P. vivax (181 parasites/μL) is 8-fold lower than that for
P. falciparum (1,460 parasites/μL), and data from PNG indi-
cates a steeper relation between the fractions of fever attrib-
utable to P. vivax infections and parasite density than for
P. falciparum.26,27 The lower pyrogenic threshold is reflected
by higher concentrations of circulating tumor necrosis factor
than for P. falciparum at equivalent peripheral parasitaemias.28
Cytokine production, endothelial activation, and pulmonary
inflammatory responses are also higher during and after
P. vivax infections compared with P. falciparum infections of
similar parasite biomass. The discrepancy between higher cyto-
kine levels and concomitant inflammatory responses on the
one hand and milder disease on the other hand compared with
P. falciparum remains unexplained.
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The low parasitemia and pyrogenic threshold of P. vivax
infections, particularly in patients with no or limited prior
exposure, challenge accurate diagnosis by light microscopy
and even more so by the currently available, sometimes less-
sensitive rapid diagnostic tests (RDTs), which have a level of
detection for P. vivax of 200−500 parasites/μL.
The problem of missing low parasite levels in endemic
areas is less about missing clinical cases and more about
transmission control, as it allows a larger pool of generally
asymptomatic carriers who are often gametocytemic and
potentially infectious to go undetected. The central diagnos-
tic challenge is identifying the reservoir of P. vivax infections
that must be reduced if P. vivax malaria is to be controlled
and eliminated. It is becoming increasingly recognized that
asymptomatic infections with low parasite densities are very
common in areas of both high and low endemicity. In cross-
sectional surveys in highly endemic PNG, 53–59% of all
P. vivax infections were submicroscopic, and 93–96% of
these were asymptomatic; in areas of lower endemicity, such
as Flores, Indonesia, with an overall prevalence of 10.5%,
nearly all (93%) were submicroscopic and none were with
fever. Similar surveys in Brazil, Cambodia, Peru, and Vanuatu
found submicroscopic infections to account for 67–89%
of all infections (overall PCR prevalence: 2.4–14.7%), with
the majority being asymptomatic. Furthermore, because
of the presence of hypnozoites, the absence of blood-stage
infections does not necessarily indicate that the person is
free of the infection. In southeast Asia, P. vivax infections
occur in 20–50% of patients soon after being treated for
P. falciparum.29 Similarly, in three community-based pediatric
cohorts in PNG, 61–100% of children who received presump-
tive treatment of only blood stages had recurrent P. vivax
infection within 3 months. Irrespective of whether they were
confirmed malaria positive by PCR at treatment, at least 60–
80% of these infections were relapses.30,31
Both light microscopy and RDTs fail to identify the
majority of P. vivax blood-stage infections, and there are
no diagnostic tests that can identify hypnozoite carriers.
Mass screening campaigns, even if based on a sensitive
molecular diagnosis of blood-stage infection, may thus miss a
large part if not the majority of people who have a recurrent
P. vivax parasitemia within 3 months. Therefore, mass drug
administration (MDA) with both an effective anti-blood-stage
as well as an anti-liver-stage drug may be one of the few ways
of attacking the P. vivax “reservoir” decisively.31,32
SEXUAL BLOOD STAGES AND TRANSMISSION
Infectious gametocytes appear in the circulation almost
simultaneously with asexual blood stages within a few days
before or after patency in P. vivax infection, and often con-
currently with relapse episodes. This extends the transmis-
sion potential before or in the absence of treatment.
There are fundamental differences between P. vivax and
P. falciparum infections with respect to the appearance of
transmission stages. While in P. falciparum the infectious
gametocytes only appear in the peripheral blood circula-
tion late in an acute infection, generally 10−14 days after
the onset of clinical symptoms, they appear earlier in pri-
mary P. vivax infections within a few days of patency and
FIGURE 3. Schematic representation of the course of a blood infection with time in Plasmodium falciparum (A) and Plasmodium vivax
(B). The vertical axis is parasite densities (sexual and asexual forms) in the blood; the horizontal axis is time since infection; both are arbitrary
and there are no units. In the absence of treatment, asexual blood parasitaemia is depicted in solid red line and gametocytemia in solid green lines.
The bars represent infectivity of gametocytes to mosquitoes. The clinical threshold parasitaemia is shown below the gray area; symptoms tend to
occur at lower parasitemias in a P. vivax compared with P. falciparum infection. In P. vivax gametocyte counts are generally one-tenth of the asex-
ual parasite counts. When effective treatment is administered at the point indicated by the vertical arrow, the parasitemia declines as depicted by
the broken red lines preventing further gametocytemia. Thus early and effective treatment will, in P. falciparum, abolish gametocytes and infectivity
to mosquitoes, whereas in P. vivax transmission has already occurred by the time treatment is administered.
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concurrently with patency in relapse episodes. Therefore,
P. falciparum cases are unlikely to have transmitted the
infection before the initiation of treatment, but this is not
necessarily so for many P. vivax cases. Thus, early diagno-
sis and treatment of P. vivax may not prevent transmission
as it usually does quite effectively for P. falciparum. There-
fore it is very important that vector control measures are
implemented if P. vivax is to be effectively controlled33,34
(see Figure 3).
Plasmodium vivax gametocytes are observed in the
majority of clinical infections, at densities of up to 10%
those of asexual parasites, and circulate for a maximum of
3 days. There is a weak association between P. vivax game-
tocyte density and mosquito infection rates. Malaria therapy
patients who were infected with P. vivax were infectious
to mosquitoes as soon as asexual parasites were present
in the blood film. This was well before the appearance of
microscopically detectable gametocytes, and such patients
remained infectious for several weeks after clinical symp-
toms had resolved and gametocytemia dropped below 10/μL.35
This infectivity of low or undetectable gametocyte densi-
ties has been confirmed by numerous studies of naturally
infected patients.
A number of studies have used molecular methods to
detect gametocytes, based on Pvs25 mRNA. These studies
found a greatly increased gametocyte detection rate compared
with microscopy and demonstrated that 50% to > 90% of all
PCR-detectable P. vivax infections had detectable levels
of gametocytemia.36,37 Another study found a better correla-
tion between gametocyte density and intensity of infection in
mosquitoes with a molecular tool for P. vivax gametocyte
detection compared with microscopy.38,39
This biological difference in the transmission modalities
of the two parasites may help explain the limited spread of
drug resistance in P. vivax. Resistance to chloroquine was
first reported for P. falciparum in the 1950s, and it spread
rapidly over the following decades to all endemic regions.
A similar, often faster pattern, of emergence and spread of
P. falciparum resistance to other antimalarial drugs has also
occurred. By contrast, the first report of chloroquine resis-
tance in P. vivax was in 1989 from PNG,40,41 and this resis-
tance appears to have spread at much slower pace, with only
isolated reports of chloroquine resistance from other parts of
the world. In a drug-sensitive P. falciparum blood infection,
early treatment will significantly reduce infectivity to mos-
quitoes. Should drug-resistant mutants have been selected,
the gametocytes that may subsequently arise will carry and
spread these mutations. In P. vivax on the other hand, trans-
mission starts before exposure to the drug. Thus, theoreti-
cally, in persons where wild-type and mutant parasites occur,
the drug-sensitive parasite will not be at a disadvantage with
respect to transmission, and consequently the selective pres-
sure for drug resistance will be reduced.33
MOSQUITO STAGES AND VECTORIAL CAPACITY
Both in the past and currently, the geographic range of
P. vivax prevalence substantially exceeds that of P. falciparum,
extending into the high latitude temperate zones. The primary
reason for this is the ability of the parasite to complete its
development cycle at lower temperatures and more quickly
than P. falciparum.
The geographical range of malaria parasites is determined
by the availability of susceptible anophelines and of envi-
ronmental conditions to allow for the time it takes for spo-
rozoites to form and reach the salivary glands following an
infectious blood meal. Although P. vivax is currently found
mainly in tropical regions,42 as is P. falciparum, its endemic
and epidemic transmission was previously common through-
out the temperate zones during summer months (including
the short subarctic summer), and these areas remain suscep-
tible to its reintroduction.43–45
While many different species of anopheline mosquitoes
can be found in nearly all regions of the world, only a subset
are susceptible to successful infection by Plasmodium para-
sites. Furthermore, the mean duration for the full develop-
ment of P. vivax in the mosquito is shorter (8–16 days) than
it is for P. falciparum (9–22 days), and can be achieved at an
average temperature of 16°C, whereas the lowest limit for
P. falciparum is 18°C.46
This explains why vector control measures deployed pri-
marily for P. falciparum have much less impact on the trans-
mission of P. vivax, as they must cover a broader range of
species (behaviors, breeding sites) to be effective for the
latter. Given the extended duration of the P. vivax infection
(as a result of relapses) and the high transmission potential
(early gametocyte production), it becomes imperative that
entomological surveys are specifically conducted to tailor
vector control measures to P. vivax.
IMMUNITY TO VIVAX MALARIA
In highly malaria-endemic areas, the burden of disease of
vivax malaria occurs earlier in life and drops earlier (after
the first 2–3 years) than falciparum. This is as a result of
more rapidly acquired clinical immunity (acquired by ∼5 years
of age) controlling blood-stage parasite densities (often to a
level only detected by PCR), rather than the acquisition of a
significant immunity against infection per se. Conversely, the
prevalence of infections detected by PCR increases with age
for both parasites. However, the molecular force of infection
(i.e., the incidence of genetically distinct infections) is higher
for vivax malaria and is largely caused by relapse.
It has long been known that P. vivax is a disease that
predominantly affects children at a younger age than
P. falciparum. Studies in areas, which are highly endemic
for both P. falciparum and P. vivax such as the island of
New Guinea, but also the western border of Thailand,
Sri Lanka, and Vanuatu show that 1) P. vivax is the pre-
dominant source of malaria infections and disease in chil-
dren < 2 years of age; 2) the incidence of P. vivax malaria
then decreases rapidly from the second year of life, whereas
P. falciparum incidence continues to increase until the fourth
year; and 3) children 5−14 years of age have acquired an
almost complete clinical immunity to P. vivax but remain at
considerable risk of P. falciparum illness despite a similar
burden of blood-stage infections (reviewed in Ref 47). As
a consequence of this remarkable difference in the rate of
acquisition of clinical immunity, in New Guinea the incidence
of P. vivax-attributable febrile illness in routine health sur-
veillance is highest in children 1–2 years of age, while that of
P. falciparum peaks in children 2–4 years of age. Although
P. vivax is a very significant source of severe illness in
infants, the proportion of P. vivax infections presenting with
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severe symptoms decreases rapidly with age, and in children
aged > 1 year, the incidence of severe P. vivax illness is sig-
nificantly lower than that caused by P. falciparum.
Similar patterns are found in the age-specific prevalence
of infection when diagnosed by light microscopy; conversely,
when infections are diagnosed by PCR, the prevalence of
both P. vivax and P. falciparum infections increase overall,
and the peak prevalence shifts into older age groups.48 This
means that submicroscopic, sub-patent parasitemia is persis-
tent even in older age groups. It has been estimated that
relapses from long-lasting liver stages account for between
60% and 80% of the burden of P. vivax blood-stage infec-
tions,30,31 with relapses caused by genetically distinct but
often related parasite clones.6,7 This explains why the inci-
dence of newly acquired, genetically distinct, P. vivax blood-
stage infections (i.e., the molecular force of blood-stage
infection) is generally higher than that of P. falciparum,
independent of the entomological inoculation rate.49
The age at first exposure may be an important modula-
tor of the natural acquisition of malarial immunity. Studies
involving nonimmune migrants to Indonesian New Guinea
who were exposed for the first time to heavy transmission
indicated that adults acquired clinical immunity to malaria
after relatively few P. falciparum infections, in contrast to
children, who remained susceptible after comparable expo-
sure. This relationship was not observed with P. vivax infec-
tions; adults did not acquire clinical immunity any more
quickly than children.50
PATHOGENESIS IN VIVAX MALARIA
Although previously believed to be a benign infection,
P. vivax is now well recognized as a significant cause of dis-
ease in all endemic areas. In addition, mortality occurs in
P. vivax, possibly related to cytoadhesion or other pathogenic
mechanisms different from those operating in P. falciparum.
All stages of P. vivax can be routinely found in blood
smears, whereas erythrocytes infected with trophozoites and
schizonts of P. falciparum adhere to vascular endothelium
and thus are rarely found in the peripheral blood, except in
overwhelming infections.51 As noted above, P. vivax prefers
to invade reticulocytes, and a reason for such preference
may be a physiological and metabolic necessity for growth
and survival in the host’s circulating erythrocytes. Plasmo-
dium vivax and related sibling species are not known to pro-
duce cytoadhesive variant ligands at the surface of infected
erythrocytes as P. falciparum-infected erythrocytes do. These
ligands bind endothelial receptors to immobilize the rigid
infected RBCs to prevent their destruction in the spleen or
while passing through capillaries. In contrast, P. vivax-infected
mature erythrocytes are highly flexible and will pass through
capillaries and splenic fenestration quite easily. The reticulo-
cyte is not yet discoid and as rigid like a mature erythrocyte,
which may aid in keeping the reticulocyte flexible.52,53
Thus, the two species have obviously evolved different
strategies to escape removal by the spleen: sequestration in
the microcirculation during advanced stages of maturation
to reduce removal by the spleen for P. falciparum versus
increased flexibility of young erythrocytes to pass unhindered
through splenic sinusoids for P. vivax. The flexibility of
infected reticulocytes may be further increased by the para-
site-induced caveola-vesicle complexes in the infected reticu-
locyte membrane (appearing on microscopic examination
of blood films as punctate spots known as Schüffner’s dots
or stippling) and other parasite-induced modifications of the
host-cell cytoskeleton.54 The preference for reticulocytes has
also prevented or hindered so far the development of contin-
uous in vitro culture of P. vivax parasites.
The absence of cytoadherence and sequestration by P. vivax
also explains some of the differences in pathogenesis and
clinical features between P. falciparum and P. vivax, and the
relative lack of severe manifestations like coma and organ
failure in the latter species. However, P. vivax is not as aviru-
lent a parasite as its nickname “benign tertian malaria” would
suggest, and may cause severe disease in some patients.55 The
symptoms of a normal uncomplicated course of infection are
very harsh and debilitating.27,56 Furthermore, there is grow-
ing evidence of severe and fatal disease syndromes despite
low levels of parasitemia. Although P. vivax is not generally
thought to sequester in the vasculature, it is possible that
severe P. vivax disease results when the bulk of biomass is
hidden in the bone marrow or spleen.57,58
GENETIC DIVERSITY OF P. VIVAX
Plasmodium vivax is more genetically diverse than
P. falciparum, potentially making it a more complex target for
therapeutic intervention. The higher genetic diversity is also
indicative of this species’ relatively stable transmission and
resilience against population bottlenecks after intervention.
Several studies have demonstrated that P. vivax is a more
genetically diverse parasite than P. falciparum both with
collections of isolates from different locations worldwide and
with field samples from co-endemic regions59–66 (Table 2).
In most countries studied outside of sub-Saharan Africa,
P. vivax is the predominant infection in the community and
at similar or higher prevalence among clinical cases. This
would partly explain the higher diversity, since under these
TABLE 2
Studies comparing Plasmodium falciparum and Plasmodium vivax genetic diversity
Region Plasmodium isolates included Dominant infection Data type
Higher
P. vivax diversity Reference
Venezuela 30 P. falciparum and 73 P. vivax isolates P. vivax Ama1 SNPs Yes 59
Worldwide reference isolates 5 isolates per species Variable Whole genome SNPs Yes 60
Venezuela 108 P. falciparum and 107 P. vivax field isolates P. vivax Microsatellites Yes 61
Vanuatu 165 P. falciparum and 100 P. vivax field isolates P. vivax msp1 and csp1 SNPs Yes 62
Cambodia 164 P. falciparum and 87 P. vivax field isolates P. vivax Microsatellites Yes 63
Papua New Guinea 308 P. falciparum and 193 P. vivax field isolates P. falciparum Microsatellites Yes 64
Indonesia 166 P. falciparum and 168 P. vivax clinical isolates P. vivax Microsatellites Yes 65
Worldwide clinical isolates 12 P. falciparum and 220 P. vivax clinical isolates Variable Whole genome SNPs Yes 66
SNPs = single nucleotide polymorphisms.
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circumstances a much higher effective population size would
be expected. However, in PNG, where P. falciparum preva-
lence was slightly higher, P. vivax also had substantially higher
diversity.64 In addition, genomic sequencing of P. vivax
populations has demonstrated that within population diversity
of P. vivax is higher than that of a small panel of P. falciparum
isolates from disparate geographic regions.66 Moreover, while
the extent of P. falciparum diversity is tightly correlated
with regional levels of transmission,67 P. vivax harbors high
genetic diversity even in low-transmission areas.68 High
diversity provides greater evolutionary potential to evade
host immunity, develop drug and vaccine resistance, and
adapt to different human and anopheline hosts. There is an
apparent contradiction between this high genetic diversity
and the fact that P. vivax immunity develops more quickly
than to P. falciparum, an overall less diverse parasite. This
may be related to a number of factors: 1) P. vivax lacks a
homologue of Plasmodium falciparum erythrocyte mem-
brane protein and thus is not thought to exhibit switching in
clonal expression of variant surface antigens; 2) a single infec-
tive mosquito bite results in one P. falciparum but five P. vivax
blood-stage infections (one primary and four relapses31), as a
result PNG children experience approximately 3 times more
distinct P. vivax blood stage infections37, despite comparable
entomological inoculation rates for both species; and 3) a
primary P. vivax infection and its relapses are generally
diverse but genetically related,7 thus results both in exposure
to known antigenic variants and boosting of allele-specific
responses. The link between genetic and antigenic diversity
of malaria parasites remains a major gap in knowledge
despite its key relevance to malaria vaccine development.
A better understanding of P. vivax diversity at different
levels of transmission would enable control programs to
mount appropriate control strategies and help monitor
whether an intervention is making an impact. Genetic diver-
sity, generated through cross-mating between distinct strains
after co-transmission to the mosquito from hosts infected with
more than one strain, is a sensitive marker for P. falciparum
transmission.62 However, since P. vivax has high levels of
diversity irrespective of the intensity of transmission, this rela-
tionship is not well defined. Comparative studies of the popu-
lation genetic structure of the two species demonstrate a less
structured population for P. vivax, indicating higher levels of
gene flow between geographic areas.60,61 A major reason for
the higher diversity and limited genetic structure of P. vivax
populations may be relapse, providing greater potential for
multiple infection65 and thus, cross-mating and further dissem-
ination than P. falciparum.66 At low transmission intensities,
increasing linkage disequilibrium has been observed indicating
more frequent transmission of highly inbred strains. In the
event of sustained low transmission, relapses would be more
likely to derive from the same inoculum, thus eventually
reducing diversity and increasing population structure.
It is unclear whether the ability to maintain high diver-
sity at low transmission for an extended period affords the
parasite population greater resilience against interventions.
Reports of P. vivax treatment failure rapidly emerged after
the introduction of sulfadoxine–pyrimethamine in PNG, yet
P. vivax chloroquine resistance emerged much more slowly
and lagged far behind that of P. falciparum. Less exposure to
drugs and higher rates of multiple infection allowing recom-
bination to breakdown any multilocus resistance haplotypes
may have slowed the emergence of resistance. High diversity
may also make the development of vaccines against P. vivax
challenging. However, the exact relationship between genetic
diversity and antigenic diversity and immunity in malaria is
likely to be quite complex. High genetic diversity of P. vivax
may reflect a more ancient parasite population rather than
adaptation to host immune responses. This is supported by
the earlier immunity described above suggesting that immune
targets in P. vivax are more antigenically conserved.32 Studies
investigating the dynamics of polymorphism in P. vivax anti-
gens will be essential to dissect the contribution to immune
escape. In addition, antimalarial interventions incorporating
drugs or vaccines will need to monitor parasite populations
closely for the emergence of resistant strains.
CONCLUSIONS
This article summarizes our current understanding of the
biology of P. vivax and the specific aspects that make it a
different parasite from P. falciparum. The main characteris-
tics of vivax malaria and their consequences and implica-
tions for research and control are summarized in Table 1.
These differences explain why P. vivax is relatively unaf-
fected by interventions tailored to control P. falciparum. The
article further suggests knowledge gaps that deserve more
investment to resolve key questions that could help identify
improved and better-tailored interventions, including trans-
mission control, diagnosis, and treatment.
The ability to develop at lower temperature and over a
shorter sporogonic cycle in the vector means that P. vivax
extends beyond tropical climates into temperate regions and
that it is less susceptible to vector control measures such as
indoor residual spraying, which reduce mosquito’ life span
and have proven effective against P. falciparum.
Having dormant forms in the liver (hypnozoites) means
that one successful infection will generate a number of para-
sitological and clinical episodes without reinfection. There-
fore, recurrent cases cannot be prevented via vector control,
though, paradoxically, successful transmission control could
reduce the burden of disease of vivax malaria more than for
P. falciparum, because avoiding one infection will result in
preventing a number of clinical episodes over several years.
Eradicating the infection remains at best a long-term goal,
until a drug effective against the hypnozoite that is also safe
for wide deployment becomes available; today we only have
8-aminoquinolines, whose use is limited by toxicity in glucose-
6-phosphate dehydrogenase deficient populations. The current
lack of reproducible in vitro and in vivo models makes it very
difficult to identify new compounds; further investments are
needed to develop adequate models.
Vivax malaria is diagnosed late, because infected people
get ill with low parasite densities, which cannot be detected
with current diagnostics, such as RDTs and microscopy, that
work for P. falciparum because of P. vivax’s preference for
reticulocytes and its low pyrogenic threshold. Delayed diag-
nosis means not only delayed treatment (hence prolonged
morbidity, especially anemia) but also ability to transmit over
an extended period. This is further amplified by the fact that
mature gametocytes appear simultaneously with asexual
forms—hence transmission occur before diagnosis and treat-
ment. Investment in new, more sensitive diagnostics adapted
to P. vivax is needed.
11PLASMODIUM VIVAX BIOLOGY
To determine the importance of low-level, asymptomatic
P. vivax infections in sustaining transmission, it is essential that
further studies into the infectious reservoir; the association of
parasitemia, gametocytemia, and infectivity; and thus the
P. vivax effective population size are conducted in areas with var-
iable transmission intensities in different vivax-endemic areas.
Plasmodium vivax has higher genetic diversity than
P. falciparum, even in areas of low transmission, which
makes it a more complex infection to study with respect to
both transmission, immunity and response to treatment. This
diversity also renders genetic markers less useful for P. vivax
epidemiology than they are for P. falciparum, especially
because we have a very limited understanding of the rela-
tionship between P. vivax diversity and transmission.
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